Anti-MDM2 autoantibodies are potential biomarkers for immunodiagnosis of HCC patients due to the low positive rate in LC, CH, and normal individuals and higher positive rate in HCC patients. This evidence concerns the gene MDM2 and laryngotracheoesophageal cleft.